Quetiapine, fluoxetine/olanzapine combo

Quetiapine, fluoxetine/olanzapine combo

• A. Adjunctive treatment for MDD
• B. Treatment-resistant MDD
• C. Clozapine, olanzapine, quetiapine, risperidone
• D. Antagonism in dopaminergic pathways

Answer: (B)

The main idea is augmentation for major depressive disorder when standard antidepressants don’t yield sufficient improvement. The fluoxetine/olanzapine combination ( marketed as Symbyax) pairs an SSRI with an atypical antipsychotic to boost response in people who don’t fully recover on antidepressants alone. This specific combo is approved for treatment-resistant depression and for bipolar depression, making treatment-resistant MDD the best description of its primary clinical use. Mechanistically, fluoxetine raises serotonin signaling, while olanzapine modulates multiple neurotransmitter systems (including dopamine and serotonin receptors) to enhance mood and reduce agitation. While augmentation in MDD can be done with various strategies, this particular pairing is best characterized by its role in treatment-resistant cases rather than as a general adjunctive approach or by its receptor antagonism alone.

The main idea is augmentation for major depressive disorder when standard antidepressants don’t yield sufficient improvement. The fluoxetine/olanzapine combination ( marketed as Symbyax) pairs an SSRI with an atypical antipsychotic to boost response in people who don’t fully recover on antidepressants alone. This specific combo is approved for treatment-resistant depression and for bipolar depression, making treatment-resistant MDD the best description of its primary clinical use. Mechanistically, fluoxetine raises serotonin signaling, while olanzapine modulates multiple neurotransmitter systems (including dopamine and serotonin receptors) to enhance mood and reduce agitation. While augmentation in MDD can be done with various strategies, this particular pairing is best characterized by its role in treatment-resistant cases rather than as a general adjunctive approach or by its receptor antagonism alone.